Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression
PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
June 1, 2025
Primary Completion Date
June 1, 2026
Study Completion Date
September 1, 2026
Conditions
Gastric Neoplasm
Interventions
DRUG
Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy
no other intervention
All Listed Sponsors
lead
Queling Liu
OTHER
NCT06977061 - Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression | Biotech Hunter | Biotech Hunter